Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Recruiting · Phase 2 · NCT05469893
Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
At a glance
- Research payments reported, 2025
- $214,938
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 52
About the trial
- Sponsor
- Irene Ghobrial, MD (with Janssen Research & Development, LLC)
- Tested
- Teclistamab (drug), Lenalidomide (drug), Dexamethasone (drug)
- Dates
- Started 2022-08-10; completion 2030-07-31
- Results posted
- Not yet
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexame…
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $214,938 in research payments for this study in 2025 (23 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $214,938
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.